Tuesday, June 28, 2011

Day 1: Avastin patients, families protest ahead of FDA hearing

Genentech Inc. ’s cancer-fighting Avastin is in front of a Food and Drug Administration panel today, a struggle that has inspired breast cancer patients and their families.
The hearing — today and Wednesday at the FDA campus in Silver Spring, Md. — will go a long way toward determining if Avastin will win full approval for metastatic breast cancer patients.
Thirty-five people signed up to make public presentations, said Karen Midthun of the FDA, who is presiding over the hearing.
Final submissions by Genentech and the FDA will continue until July 28. FDA Commissioner Margaret Hamburg will make the final decision.

No comments:

Post a Comment